Table 3.
ROI | FA |
MD |
AD |
RD |
||||
---|---|---|---|---|---|---|---|---|
r | pFDR | r | pFDR | r | pFDR | r | pFDR | |
Substantia Nigra | +0.058 | 0.777 | +0.015 | 0.941 | −0.016 | 0.939 | +0.201 | 0.692 |
Caudate | +0.543 | 0.028 | −0.661 | 0.002 | −0.628 | 0.007 | −0.635 | 0.003 |
Pallidum | +0.382 | 0.126 | −0.112 | 0.682 | −0.032 | 0.939 | −0.110 | 0.692 |
Putamen | −0.096 | 0.747 | +0.320 | 0.391 | +0.345 | 0.294 | +0.0211 | 0.692 |
Thalamus | +0.128 | 0.747 | −0.156 | 0.666 | −0.175 | 0.688 | −0.164 | 0.692 |
Red nucleus | −0.431 | 0.098 | −0.236 | 0.572 | −0.275 | 0.406 | +0.024 | 0.906 |
Subthalamic Nucleus | +0.239 | 0.420 | −0.284 | 0.666 | −0.201 | 0.706 | +0.123 | 0.692 |
AD, axial diffusivity; CBF, cerebral blood flow; FA, fractional anisotropy; FDR, false discovery rate; MD, mean diffusivity; PD, Parkinson’s disease; RD, radial diffusivity; ROI, region of interest. P-values lower than 0.05 were considered significant (in bold).